Incyte has filed a patent for a method of reducing itch in patients with atopic dermatitis. The method involves administering a topical cream containing either 0.75% or 1.5% ruxolitinib twice a day. GlobalData’s report on Incyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Incyte, Peptide pharmacophores was a key innovation area identified from patents. Incyte's grant share as of September 2023 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Method for reducing itch in patients with atopic dermatitis
A recently filed patent (Publication Number: US20230293528A1) describes a method for treating mild to moderate atopic dermatitis in human patients. The method involves administering a topical formulation containing 0.75% (w/w) of ruxolitinib, or a pharmaceutically acceptable salt of ruxolitinib, twice a day to the patient's skin. The treatment is recommended for patients with a Body Surface Area (BSA) of atopic dermatitis involvement ranging from 3% to 20% at baseline and an itch Numerical Rating Scale score of =4 at baseline. The administration of the topical formulation should be continued for at least 8 weeks.
The patent also includes additional claims for treating moderate atopic dermatitis. In this case, the method involves administering the same topical formulation twice a day for at least 8 weeks. The patient should have a BSA of atopic dermatitis involvement ranging from 3% to 20% at baseline and an itch Numerical Rating Scale score of =4 at baseline. The patient should achieve at least a 4 point reduction in itch Numerical Rating Scale score from baseline at week 8 with administration. Additionally, the patient should achieve IGA treatment success (IGA-TS) with a score of 0 (clear) or 1 (almost clear) and =2 grade improvement from baseline at week 8. The patient should be aged 12 or older, have a history of atopic dermatitis for at least 2 years, and have an Investigator's Global Assessment score of 2 to 3 at baseline.
The patent also mentions specific criteria for patients who can benefit from the treatment, such as having a BSA of atopic dermatitis involvement of =10% at baseline and an Eczema Area and Severity Index score of =16 at baseline. The patent further specifies that the ruxolitinib used in the formulation can be ruxolitinib phosphate.
Overall, the patent describes a method for treating mild to moderate atopic dermatitis using a topical formulation containing ruxolitinib. The treatment is recommended for patients with specific baseline characteristics and involves continued administration for at least 8 weeks. The patent also includes additional criteria for treating moderate atopic dermatitis, including achieving specific reduction in itch scores and IGA treatment success.
To know more about GlobalData’s detailed insights on Incyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
